Home » Uncategorized » Metastatic Melanoma Treatment: Experimental Drug Shows Promise

Researchers have announced that a new experimental drug known as “PLX4032” has shown beneficial results in 80% of the patients with metastatic melanoma. The drug targets a specific genetic mutation. Researchers are hopeful that the drug may show positive results with other tumors that share the same genetic defect.

Metastatic Melanoma Treatment

PLX4032 specifically targets the BRAF gene/protein which stimulate the growth of tumor cells. In around 50% of melanoma, a mutated BRAF gene is present which doesn’t shut off , causing tumor growth. The drug was developed by Plexxikon Inc. of Berkeley and licensed to Roche Pharmaceuticals.

The study was conducted by Dr. Keith Flaherty of the Massachusetts General Hospital in Boston, Dr. Paul Chapman of the Memorial Sloan-Kettering Cancer Center in New York and their colleagues and the results were published in the New England Journal of Medicine. The study involved 32 patients with metastatic melanoma and BRAF mutation. In 26 of those patients, the tumors shrank by 32 percent. Some reduction in size was observed in two others. In two patients, the tumors disappeared completely.

Via: Los Angeles Times

Outsmart cancer

  • "Cancer does not have to be a death sentence"

    Let’s Find Out How To Be Cancer Proof!